David R. Spigel, MD, FASCO, on Guiding Adjuvant Chemotherapy Using a Molecular Assay

Posted: Thursday, June 19, 2025

David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, offers insights on the role of a 14-gene molecular assay for planning adjuvant chemotherapy use in patients with stage Ia–IIa non–small cell lung cancer, noting how multiple members of the care team may use the information gleaned from the test in caring for patients.

---